RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: Evidence for distinct molecular pathways in thyroid follicular carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 5, 2003, Pages 2318-2326

  Nikiforova, Marina N ^a   Lynch, Roy A ^b   Biddinger, Paul W ^a   Alexander, Erik K ^c   Dorn II, Gerald W ^b   Tallini, Giovanni ^d   Kroll, Todd G ^e   Nikiforov, Yuri E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; FEMALE; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; MALE; MOLECULE; NUCLEOTIDE SEQUENCE; ONCOCYTOMA; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONSET AGE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TECHNIQUE; TECHNOLOGY; THYROID FOLLICULAR CARCINOMA; THYROID TUMOR; TUMOR VOLUME;

ADENOCARCINOMA, FOLLICULAR; ADENOMA, OXYPHILIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CODON; DNA-BINDING PROTEINS; GALECTIN 3; GENE REARRANGEMENT; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; PAIRED BOX TRANSCRIPTION FACTORS; POINT MUTATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID NEOPLASMS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0012683188     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021907     Document Type: Article

References (42)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648
2. Mazzaferri EL 1993 Management of a solitary thyroid nodule. N Engl J Med 328:553-559
3. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, Vecchione A, Tecce R, Larsson O 2001 Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357:1644-1650
4. Xu XC, el-Naggar AK, Lotan R 1995 Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 147:815-822
5. Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG, Bartolazzi A 1999 Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol 17:3494-3502
6. Chiariotti L, Berlingieri MT, De Rosa P, Battaglia C, Berger N, Bruni CB, Fusco A 1992 Increased expression of the negative growth factor, galactoside-binding protein, gene in transformed thyroid cells and in human thyroid carcinomas. Oncogene 7:2507-2511
7. Miettinen M, Karkkainen P 1996 Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours. Virchows Arch 429:213-219
8. Sack MJ, Astengo-Osuna C, Lin BT, Battifora H, LiVolsi VA 1997 HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Mod Pathol 10:668-674
9. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL 2001 Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14:338-342
10. Lloyd RV 2001 Distinguishing benign from malignant thyroid lesions: galectin 3 as the latest candidate. Endocr Pathol 12:255-257
11. Nascimento MC, Bisi H, Alves VA, Longatto-Filho A, Kanamura CT, Medeiros-Neto G 2001 Differential reactivity for galectin-3 in Hurthle cell adenomas and carcinomas. Endocr Pathol 12:275-279
12. Herrmann ME, LiVolsi VA, Pasha TL, Roberts SA, Wojcik EM, Baloch ZW 2002 Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 126:710-713
13. Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B, Wynford-Thomas D 1989 High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4:159-164
14. Suarez HG, du Villard JA, Severino M, Caillou B, Schlumberger M, Tubiana M, Parmentier C, Monier R 1990 Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 5:565-570
15. Esapa CT, Johnson SJ, Kendall-Taylor P, Lennard TW, Harris PE 1999 Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf) 50:529-535
16. Motoi N, Sakamoto A, Yamochi T, Horiuchi H, Motoi T, Machinami R 2000 Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathol Res Pract 196:1-7
17. Lemoine NR, Mayall ES, Wyllie FS, Farr CJ, Hughes D, Padua RA, Thurston V, Williams ED, Wynford-Thomas D 1988 Activated ras oncogenes in human thyroid cancers. Cancer Res 48:4459-4463
18. Basolo F, Pisaturo F, Pollina LE, Fontanini G, Elisei R, Molinaro E, Iacconi P, Miccoli P, Pacini F 2000 N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 10:19-23
19. Namba H, Rubin SA, Fagin JA 1990 Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4:1474-1479
20. Schark C, Fulton N, Jacoby RF, Westbrook CA, Straus 2nd FH, Kaplan EL 1990 N-ras 61 oncogene mutations in Hurthle cell tumors. Surgery 108:994-1000
21. Tallini G, Hsueh A, Liu S, Garcia-Rostan G, Speicher MR, Ward DC 1999 Frequent chromosomal DNA unbalance in thyroid oncocytic (Hurthle cell) neoplasms detected by comparative genomic hybridization. Lab Invest 79:547-555
22. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Splegelman BM, Fletcher JA 2000 PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 289:1357-1360
23. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE 2002 PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 26:1016-1023
24. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, Leite V 2002 Expression of PAX8-PPAR gamma I rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87:3947-3952
25. French CA, Alexander EK, Cibas ES, Nose V, Faquin W, Garber J, Moore F, Fletcher JA, Larsen P, Kroll TG, Genetic and biologic subgroups of early stage follicular thyroid cancer. Am J Pathol, in press
26. Martelli ML, Iuliano R, Le Pera I, Sama I, Monaco C, Cammarota S, Kroll T, Chiariotti L, Santoro M, Fusco A 2002 Inhibitory effects of peroxisome proliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab 87:4728-4735
27. Rosai J, Carcangiu ML, DeLellis RA 1992 Tumors of the thyroid gland. Atlas of tumor pathology. Washington: Armed Forces Institute of Pathology
28. LiVolsi VA 1990 Surgical pathology of the thyroid. Philadelphia: WB Saunders Co.
29. Nikiforov YE, Nikiforova MN, Gnepp DR, Fagin JA 1996 Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident. Oncogene 13:687-693
30. Nikiforova MN, Caudill CM, Biddinger P, Nikiforov YE 2002 Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int J Surg Pathol 10:15-22
31. Argani P, Zakowski MF, Klimstra DS, Rosai J, Ladanyi M 1998 Detection of the SYT-SSX chimeric RNA of synovial sarcoma in paraffin-embedded tissue and its application in problematic cases. Mod Pathol 11:65-71
32. Elenitoba-Johnson KS, Bohling SD, Wittwer CT, King TC 2001 Multiplex PCR by multicolor fluorimetry and fluorescence melting curve analysis. Nat Med 7:249-253
33. Nakao M, Janssen JW, Seriu T, Bartram CR 2000 Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using LightCycler technology. Leukemia 14:312-315
34. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP 1997 Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 22:130-131, 134-138
35. Lynch RA, Wagoner L, Li S, Sparks L, Molkentin J, Dorn 2nd GW 2002 Novel and nondetected human signaling protein polymorphisms. Physiol Genomics 10:159-168
36. Roque L, Castedo S, Clode A, Soares J 1993 Deletion of 3p25->pter in a primary follicular thyroid carcinoma and its metastasis. Genes Chromosomes Cancer 8:199-203
37. Lemoine NR, Staddon S, Bond J, Wyllie FS, Shaw JJ, Wynford-Thomas D 1990 Partial transformation of human thyroid epithelial cells by mutant Ha-ras oncogene. Oncogene 5:1833-1837
38. Jones CJ, Kipling D, Morris M, Hepburn P, Skinner J, Bounacer A, Wyllie FS, Ivan M, Bartek J, Wynford-Thomas D, Bond JA 2000 Evidence for a telomere-independent "clock" limiting RAS oncogene-driven proliferation of human thyroid epithelial cells. Mol Cell Biol 20:5690-5699
39. Santelli G, de Franciscis V, Portella G, Chiappetta G, D'Alessio A, Califano D, Rosati R, Mineo A, Monaco C, Manzo G, et al. 1993 Production of transgenic mice expressing the Ki-ras oncogene under the control of a thyroglobulin promoter. Cancer Res 53:5523-5527
40. Segev DL, Saji M, Phillips GS, Westra WH, Takiyama Y, Piantadosi S, Smallridge RC, Nishiyama RH, Udelsman R, Zeiger MA 1998 Polymerase chain reaction-based microsatellite polymorphism analysis of follicular and Hurthle cell neoplasms of the thyroid. J Clin Endocrinol Metab 83:2036-2042
41. Zedenius J, Wallin G, Svensson A, Grimelius L, Hoog A, Lundell G, Backdahl M, Larsson C 1995 Allelotyping of follicular thyroid tumors. Hum Genet 96:27-32
42. Grebe SK, McIver B, Hay ID, Wu PS, Maciel LM, Drabkin HA, Goellner JR, Grant CS, Jenkins RB, Eberhardt NL 1997 Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma. J Clin Endocrinol Metab 82:3684-3691